# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $7 price target.
RMAT designation follows FDA's review of available safety and efficacy data from the first three patients dosed with the lo...
Cantor Fitzgerald analyst Kristen Kluska reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight and maintains $7 p...
Cantor Fitzgerald analyst Kristen Kluska reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight and maintains $7 p...
Cantor Fitzgerald analyst Kristen Kluska reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight and maintains $7 p...
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Friday.
Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $7 price target.
U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday.